The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Transcriptional Activation by Tetracyclines in Mammalian Cells
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., & Bujard, H. (1995) · Science · doi:10.1126/science.7792603 · Cited by 2,488 · cited 1×
“gif" NDATA ITEM> ]> We mated transgenic mouse lines expressing the reverse tetracycline-dependent transcriptional activator (rtTA) under the control of the mouse mammary tumor virus long terminal repeat (MMTV-LTR; mouse line named Tg(rtTA)1lach called here MTB), to a second transgenic line containing exons 2 and 3 of…”
BackgroundReversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Coller, H. A., Grandori, C., Tamayo, P., Colbert, T., Lander, E. S., Eisenman, R. N., & Golub, T. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3260 · Cited by 823
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
The ornithine decarboxylase gene is a transcriptional target of c-Myc.
Bello-Fernandez, C., Packham, G., & Cleveland, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7804 · Cited by 777
Reversible Activation of c-Myc in Skin
Pelengaris, S., Littlewood, T., Khan, M., Elia, G., & Evan, G. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80350-0 · Cited by 468
Leder, A., Pattengale, P. K., Kuo, A., Stewart, T. A., & Leder, P. (1986) · Cell · doi:10.1016/0092-8674(86)90280-1 · Cited by 423
Cited by
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
DNA secondary structures: stability and function of G-quadruplex structures
Bochman, M. L., Paeschke, K., & Zakian, V. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3296 · Cited by 1,446
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Dang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188
c-MYC: more than just a matter of life and death
Pelengaris, S., Khan, M., & Evan, G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc904 · Cited by 1,178
Transcriptional regulation and transformation by Myc proteins
Adhikary, S., & Eilers, M. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1703 · Cited by 1,131
MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Gabay, M., Li, Y., & Felsher, D. W. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014241 · Cited by 818
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Cancer revoked: oncogenes as therapeutic targets
Felsher, D. W. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1070 · Cited by 556
The Myc oncoprotein as a therapeutic target for human cancer
Vita, M., & Henriksson, M. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.015 · Cited by 552
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
Camarda, R., Zhou, A. Y., Kohnz, R. A., Balakrishnan, S., Mahieu, C., Anderton, B., Eyob, H., Kajimura, S., Tward, A., Krings, G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4055 · Cited by 528
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
Sarkisian, C. J., Keister, B. A., Stairs, D. B., Boxer, R. B., Moody, S. E., & Chodosh, L. A. (2007) · Nature Cell Biology · doi:10.1038/ncb1567 · Cited by 490
Self-citationThe myc Oncogene: arvelouslomplex
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)84004-0 · Cited by 463
Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 448
Oct-3/4 is a dose-dependent oncogenic fate determinant
Gidekel, S., Pizov, G., Bergman, Y., & Pikarsky, E. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00270-8 · Cited by 441
Zhan, L., Rosenberg, A., Bergami, K. C., Yu, M., Xuan, Z., Jaffe, A. B., Allred, C., & Muthuswamy, S. K. (2008) · Cell · doi:10.1016/j.cell.2008.09.045 · Cited by 436
c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells
Wang, J., Wang, H., Li, Z., Wu, Q., Lathia, J. D., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003769 · Cited by 429
Signaling Pathways in Mammary Gland Development
Hennighausen, L., & Robinson, G. W. (2001) · Developmental Cell · doi:10.1016/s1534-5807(01)00064-8 · Cited by 422
Chakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X.-H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46382 · Cited by 391
Direct Evidence for Epithelial-Mesenchymal Transitions in Breast Cancer
Trimboli, A. J., Fukino, K., de Bruin, A., Wei, G., Shen, L., Tanner, S. M., Creasap, N., Rosol, T. J., Robinson, M. L., Eng, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2148 · Cited by 368
Strategies for the discovery and development of therapies for metastatic breast cancer
Eckhardt, B. L., Francis, P. A., Parker, B. S., & Anderson, R. L. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2372 · Cited by 349
A pathway-based classification of human breast cancer
Gatza, M. L., Lucas, J. E., Barry, W. T., Kim, J. W., Wang, Q., D. Crawford, M., B. Datto, M., Kelley, M., Mathey-Prevot, B., Potti, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912708107 · Cited by 347
Moody, S. E., Sarkisian, C. J., Hahn, K. T., Gunther, E. J., Pickup, S., Dugan, K. D., Innocent, N., Cardiff, R. D., Schnall, M. D., & Chodosh, L. A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00212-x · Cited by 345
Self-citationTumor reversion: Correction of malignant behavior by microenvironmental cues
Kenny, P. A., & Bissell, M. J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11491 · Cited by 326
The New Era in Cancer Research
Varmus, H. (2006) · Science · doi:10.1126/science.1126758 · Cited by 308
Targeting MYC Expression through G-Quadruplexes
Brooks, T. A., & Hurley, L. H. (2010) · Genes & Cancer · doi:10.1177/1947601910377493 · Cited by 301
Brooks, T. A., & Hurley, L. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2733 · Cited by 294
Hutchin, M. E., Kariapper, M. S. T., Grachtchouk, M., Wang, A., Wei, L., Cummings, D., Liu, J., Michael, L. E., Glick, A., & Dlugosz, A. A. (2005) · Genes & Development · doi:10.1101/gad.1258705 · Cited by 274
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261
Gene expression phenotypic models that predict the activity of oncogenic pathways
Huang, E., Ishida, S., Pittman, J., Dressman, H., Bild, A., Kloos, M., D'Amico, M., Pestell, R. G., West, M., & Nevins, J. R. (2003) · Nature Genetics · doi:10.1038/ng1167 · Cited by 263
Myc Recruits P-TEFb to Mediate the Final Step in the Transcriptional Activation of the cad Promoter
Eberhardy, S. R., & Farnham, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207441200 · Cited by 262
The MYC oncogene is a global regulator of the immune response
Casey, S. C., Baylot, V., & Felsher, D. W. (2018) · Blood · doi:10.1182/blood-2017-11-742577 · Cited by 259
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate
Korangath, P., Teo, W. W., Sadik, H., Han, L., Mori, N., Huijts, C. M., Wildes, F., Bharti, S., Zhang, Z., Santa-Maria, C. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1200 · Cited by 182
Metastatic pancreatic cancer is dependent on oncogenic Kras in mice
Collins, M. A., Brisset, J.-C., Zhang, Y., Bednar, F., Pierre, J., Heist, K. A., Galbán, C. J., Galbán, S., & di Magliano, M. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049707 · Cited by 178
MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits
Liu, H., Radisky, D. C., Yang, D., Xu, R., Radisky, E. S., Bissell, M. J., & Bishop, J. M. (2012) · Nature Cell Biology · doi:10.1038/ncb2491 · Cited by 181
Metabolic shifts in residual breast cancer drive tumor recurrence
Havas, K. M., Milchevskaya, V., Radic, K., Alladin, A., Kafkia, E., Garcia, M., Stolte, J., Klaus, B., Rotmensz, N., Gibson, T. J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89914 · Cited by 168
Contributions of Myc to tumorigenesis
Lutz, W., Leon, J., & Eilers, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00036-7 · Cited by 177
Fleming, J. B., Shen, G.-L., Holloway, S. E., Davis, M., & Brekken, R. A. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0206 · Cited by 176
Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression
Beverly, L. J., Felsher, D. W., & Capobianco, A. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1664 · Cited by 157
Mammary epithelial cell transformation: Insights from cell culture and mouse models
Dimri, G., Band, H., & Band, V. (2005) · Breast Cancer Research · doi:10.1186/bcr1275 · Cited by 120
Deschênes, J., Bourdeau, V., White, J. H., & Mader, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.c700030200 · Cited by 99
c-MYC—Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease
Zheng, K., Cubero, F., & Nevzorova, Y. (2017) · Genes · doi:10.3390/genes8040123 · Cited by 84
Weinstein, B. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_1 · Cited by 17
Metadata
- Authors
- D'Cruz, C. M., Gunther, E. J., Boxer, R. B., Hartman, J. L., Sintasath, L., Moody, S. E., Cox, J. D., Ha, S. I., Belka, G. K., Golant, A., Cardiff, R. D., & Chodosh, L. A.
- Venue
- Nature Medicine
- Published
- 2001-02
- Volume
- 7
- Issue
- 2
- Pages
- 235-239
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1500013333
- Cited by
- 418
- References
- 22
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.